Inflammation panel update

April 3, 2019. Olink® INFLAMMATION is the most widely used and most frequently cited Olink panel. After listening to feedback from our customers, we have made significant improvements to two key assays within this panel of 92 inflammation-related proteins. Our new assays for Tumor Necrosis Factor (T...

Summa Equity acquires Olink Proteomics

TUE, MAR 12, 2019 08:30 CET Summa Equity acquires Olink Proteomics, a Swedish life science company that has developed a unique technology for human biomarker discovery, targeting the global biopharma and academic research and discovery markets. Olink’s purpose is to enable precision...

Olink into Asia

A new member of the Olink family joins us in Singapore! We are delighted to introduce Dr. Wen Jing Sim, who will represent Olink Proteomics as our first Business Development Manager in Asia. Wen Jing will be based in Singapore, and support new and existing customers based in a broad region includin...

Available now- a new protein biomarker panel for oncology

December 13, 2018. A new 92-plex protein panel containing a combination of  established and exploratory markers focused on oncology is now available for immediate shipment as kits, or via our Analysis Service. This panel provides a perfect complement to our existing panel, Olink® O...

Coming soon – a new protein biomarker panel for oncology

A new 92-plex protein panel containing a combination of  established and exploratory markers focused on oncology will be available in December for shipment as kits, or via our Analysis Service. This panel will provide a perfect complement to our existing panel, Olink® ONCOLOGY II, enabling oncologi...

Olink wins major Frost & Sullivan award

Frost & Sullivan has recognized Olink Proteomics with its 2018 Global Enabling Technology Leadership Award for the development of our multiplex cardiovascular disease (CVD) panels. Each year, Frost & Sullivan presents this award to a company that develops a pioneering technology that not onl...

New office and lab facilities for Olink’s US organization

In the less than two and a half years since Olink Proteomics established a base for its US operations in Watertown MA, the size of the US organization and its customer-base have grown dramatically. To reflect and build on this level of success, the US organization has just moved into bigger, better ...

Protein biomarkers making an impact in clinical trials for Atopic Dermatitis.

DS Biopharma have announced in a press release that oral treatment with the immunomodulating, bioactive lipid, DS107 reversed the molecular signature of Atopic Dermatitis (AD) patients in a phase 2b clinical trial. Protein data generated using Olink’s biomarker panels provided evidence of the favora...

Petter Brodin – in his own words

A story from the Olink user community. Petter Brodin talks about his landmark study (Olin et al, 2018), published in Cell, “Stereotypic immune system development in newborn children“. Biography Petter Brodin studied medicine at Karolinska Institutet an...

White paper on study design now available

“Strategies for design of protein biomarker studies”  is a new white paper that describes important aspects of study design to consider when planning your future research. These include a well-defined study objective, adequate sample size, control of confounding factors and...